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C.  Main Section of the Proposal  
 
1) Overall Goal & Objectives: Describe the overall aim for this initiative. List the key objectives 
and how they are intended to address the established need for this initiative.   
 
Under the auspices of the MGH Antimicrobial Stewardship Program (ASP), this inpatient-based 
quality improvement initiative will target inappropriate prescribing of daptomycin and linezolid, 
two powerful antibiotics increasingly used in the inpatient setting. Specifically, a 
multidisciplinary team will identify current inpatients receiving greater than 72 hours of 
treatment with daptomycin or linezolid and assess treatment appropriateness; for cases 
without microbiological data supporting continued use of these antibiotics, clinicians will 
receive targeted, evidence-based educational feedback about de-escalation strategies. The 
primary goal of reducing inappropriate prescribing of daptomycin and linezolid will be 
measured by comparing days of therapy (DOT) / 1000 patient days pre- and post- intervention. 
In parallel, a case-based clinician education program will be developed and deployed, with 
impact of both interventions measured through pre- and post-surveys of clinicians. 
 
2) Technical Approach: Describe how this initiative will meet the aim of the specific area of 
interest for the RFP. 
 
A:  Current Assessment of Need in Target Area 
 
i. Baseline Data, Initial Metrics, Gap Analysis 
Prior work has demonstrated physicians’ deviation from national guideline-based antimicrobial 
therapy.
1 Educational materials, such as the Joint Commission Resources Antibiotic Resistance 
Toolkit, are widely available, and studies have shown that clinicians are receptive to 
antimicrobial prescribing recommendations. However, there are few data demonstrating the 
impact of quality-improvement interventions on physician knowledge, prescribing practices and 
on total antimicrobial use.
2 
The proposed intervention is built upon preliminary work of the ASP. In the last several years, 
increased utilization of carbapenems was noted by the ASP. In response to an assessment, a 
team was created to undertake daily review of existing carbapenem orders, including chart and 
microbiological review, and provide direct feedback to teams regarding the appropriateness of 
the use of meropenem, ertapenem and imipenem. An analysis of the impact of this 
intervention in 2011 demonstrated a 12% reduction in volume. Despite this, non-
microbiologically-driven prescribing continues indicating a need for systematic educational 
initiatives and objective analysis of the impact of such interventions.  4 
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Studies indicate that up to 50 percent of antimicrobial use is inappropriate
3, exposing patients 
to potential medication toxicity and contributing to antimicrobial resistance.
4  Increasing 
resistance to linezolid has been reported in association with extensive use
5-7, and developing 
resistance to daptomycin has been demonstrated.
8 The Centers for Disease Control and 
Prevention, the Joint Commission on the Accreditation of Healthcare Organizations and the 
Infectious Diseases Society of America (IDSA)have identified improving appropriate antibiotic 
use as a national public health priority.
9-11 Studies demonstrate that although physicians believe 
they practice according to published evidence-based antimicrobial guidelines, they largely fail 
to choose guideline-concordant therapy when tested.
1 While studies have shown that clinicians 
are receptive to antimicrobial prescribing recommendations following post-prescription review, 
there is a paucity of data demonstrating the impact of such interventions on physician 
prescribing practices and on total antimicrobial use.
2 
MGH has approximately 50,000 inpatient admissions a year, and 20 to 25 percent of MGH 
inpatients are MRSA-, VRE- or combined MRSA/VRE colonized; approximately 2 percent of MGH 
inpatients receive daptomycin or linezolid. Internal audits performed by the MGH Antimicrobial 
Stewardship Program have demonstrated that, compared to physicians at similar medical 
institutions, those at MGH treat a larger percentage of patients with daptomycin and linezolid 
(Table A), and for a longer duration (Table B). These data underscore the need for targeted, 
educational interventions to promote appropriate antimicrobial prescribing. 
    
Table A  Table B 
 
                                       (Note: Comparator institutions de-identified) 
 
ii. Primary Audience: Infectious Disease Specialists and multidisciplinary teams who prescribe 
daptomycin and linezolid or work with patients receiving these two powerful antibiotics in an 
inpatient setting.  
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B.  Intervention Design and Methods 
  
The activity will utilize the MGH Academy’s state-of-the-art enterprise-level learning (LMS) and 
content management system (CMS) to guide participants through the performance 
improvement process (http://www.mghacademy.org) The LMS was designed to complement 
the capabilities of the Partners HealthCare electronic medical record system (5.6 million 
patients accessed from over 70,000 active desktops within the Partners HealthCare System). 
The LMS system has been routinely used by over 35,000 health care providers – including 
registrants from 121 countries (95 percent US based) and has had hundreds of thousands of 
disseminated activities per year. The LMS has been built and customized to be easily accessible-
- facilitating data collection and dissemination of outcomes data with minimal disruption to 
provider workflow.  
 
The LMS is currently being used in similar MGH initiatives, including PI-CME programs in HIV 
and ADHD (on file). A sample screen shot from the Academy’s PI CME platform can be seen in 
figure below.  
 
This system has been built and customized to support quality improvement initiatives. The LMS 
and CMS include the following features: 
•  Chart abstraction tools and self-assessment surveys 
•  Automated data import 
•  Real-time measure calculation  
•  Benchmarking and comparison to peers and national standards 
•  Data extraction and analysis reporting 
•  Multimedia educational content and dynamic performance improvement modules 
•  Virtual “lunch and learn” forums that facilitate Stage B group problem solving  
•  Resource center 
•  Online activity evaluation 
•  Automated Quality Review Board (QRB) and Continuing Professional Development (CPD) 
integrated committee reviews (e.g., linking PI/CME and MOC IV program development) 
•  Automated appropriate certificate generation  
  6 
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This educational initiative will be conducted in a 3-stage quality improvement format: 
STAGE A: Learn from Current Practice:  
Data will be collected on DOT/1000 patient days for daptomycin and linezolid for the year prior 
to the intervention to serve as the baseline metric. A survey instrument using REDCap 
(Research electronic data capture), a secure web-based application hosted by Partners 
Research Computing, will be developed. A cohort of inpatient clinicians—house officers,  
hospitalist staff, physicians assistants and nurse practitioners will be surveyed regarding current 
antimicrobial prescribing practices and understanding of and adherence to institutional and 
national guidelines. This will provide a baseline knowledge assessment.  
PI CME Platform: the platform has been adaptable to training sessions across the US where 
providers learn about evidence-based adoption of best practice standards into routine clinical 
practice. As an example, 176 learners participated in the Academy’s “Cognitive Behavioral 
Therapy” training program and were required to pay tuition. 7 
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The Research Team has prior experience with such surveys. For example, in February 2012 the 
team completed a pre-post quality improvement intervention survey of over 400 resident 
physicians at MGH regarding their knowledge of prevention of catheter-associated urinary tract 
infections. The survey was completed in October 2012 the data are under analysis. In the past 
two years, the research team has designed, implemented and published two additional national 
surveys related to infection control practices. 
12,13 
 
STAGE B: Apply Quality Improvement Strategies to Patient Care:  
The specific physician behavior targeted in Stage B is de-escalation of therapy after an empiric 
trial (i.e. 72 hours) of either daptomycin or linezolid. A post-prescription audit will be instituted 
to identify patients receiving daptomycin and linezolid at or exceeding 72 hours from initiation 
of treatment.  During daily rounds, multidisciplinary teams will review these patients’ charts 
and microbiological data, and make specific recommendations to teams caring for patients. De-
escalation strategies will be recommended in cases where: 
 
1) Microbiological data exist that do not support use of either drug (e.g. vancomycin-sensitive 
enterococcus isolated from the urine, no indication to continue with linezolid therapy) 
 
or 
 
2) No microbiological data exist at all, and de-escalation should be considered.  
 
In cases in which microbiological data do support continued use, no intervention will occur. This 
daily review will generate feedback in the form of email/page/discussion with the team.  We 
have experience with multidisciplinary team review of antibiotic prescribing; such teams are 
currently in place for review of carbapenem prescribing, and will have their role expanded to 
include this project. 
 
Using the MGH Academy’s innovative Learning Management System, a case-based Interactive 
Learning Module (ILM) will be developed to address the clinical and knowledge gaps identified 
in Stage A. An example of an ILM may be found at: www.mghacademy.org/ILMdemo. 
 
This learning module will also include an interactive online clinical simulation using our 
Computer Simulation Assessment Tool (CSAT); in this simulation exercise, participants will be 
shown video vignettes of clinical interviews during which they will choose from a menu of 
treatment and discussion options that mirror the choices typically faced in an actual clinical 
encounter. An example of a CSAT may be found at: www.mghacademy.org/CSATdemo. 
 
Data derived from the interactive and on-line clinical simulation tools provide additional 
documented gap analyses for iterative educational interventions and/or User Interface (UI) 
ordering improvements (e.g., changes in EMR template and/or ‘flags’).  8 
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The MGH Academy has significant experience in using this approach to evaluate clinician 
performance.  For example, in a 2011 program, 123 participants completed a CSAT on the 
evaluation of insomnia in a patient with treatment-resistant depression (full data on file). In this 
CSAT, participants’ performance was reflected in their ability to identify necessary elements of 
an optimal clinical evaluation (TABLE C). 
 
TABLE C 
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Additionally, diagnostic choices were stratified by participant discipline (TABLE D): 
TABLE D 
 
 
MGH Psychiatry Academy CSAT modules are also a current component of the MGH clinician re-
credentialing process, and have been used to evaluate the performance of over 400 clinicians 
to date.  
Participants will also fill out an evaluation / self-reflection form to give feedback about the 
educational interventions and any potential barriers they believe may impede adaptation of the 
recommendations. 
STAGE C: Evaluate Results of the Quality Improvement Initiative:  
Data will be collected about response to recommendations given during multidisciplinary daily 
rounds. Data will be collected on DOT/1000 patient days for daptomycin and linezolid for the 
year of the intervention to evaluate changes in DOT/1000 patient days resulting from the 
intervention. The clinicians polled in Stage A will be surveyed again (post- educational 
intervention) to estimate the impact on their prescribing practices and understanding of and 
adherence to national guidelines. Participants will also fill out an evaluation / self-reflection 
form to summarize changes in practice, process or outcomes that resulted from this initiative. 10 
 Grant ID: 044182 Partners HealthCare System 
Improving the Use of Antimicrobials to Treat Gram-Positive Infections: 
Encouraging Appropriate Use and Minimizing Antimicrobial Resistance 
C.  Evaluation Design  
Describe how you will determine if the practice gap identified in the needs assessment was 
addressed for the target group in terms of the metrics used for the needs assessment. 
DOT/1000 patient days for daptomycin and linezolid will be compared pre- and post- 
educational intervention to determine changes in duration of antimicrobial treatment. In our 
experience, DOT/1000 patient days is preferable to mean DOT as an accurate reflection of 
utilization. For example, while mean DOT is affected by length of stay, DOT/1000 patient days is 
not and can, therefore, more accurately capture utilization. 
Indicate how you will determine if the target audience was fully engaged in the intervention. 
Because there is extensive communication among clinicians at MGH who often work in 
multidisciplinary teams, the research team does not believe it is feasible to establish a 
randomized control group that is isolated from the project’s interventions. We have substantial 
data regarding current clinician prescribing practices, and will evaluate data pre- and post- 
intervention to discern effects of the intervention. Specifically, clinicians’ responses to polling 
questions pre- and post- educational intervention will be compared to determine changes to 
their knowledge of practices and understanding of/adherence to institutional and national 
guidelines, while analyses of utilization pre- and post- intervention will allow for an assessment 
of whether or not the educational interventions (CSAT and multidisciplinary rounds) lead to the 
desired change in prescribing patterns. Clinicians’ evaluation/self-reflection forms from Stage B 
and Stage C will also be reviewed to assess participants’ engagement in the intervention. 
Quantify the amount of change expected from this intervention in terms of your target 
audience (e.g., a 10% increase over baseline or a decrease in utilization from baseline 
between 20-40%) 
The goal of this initiative is to reduce DOT/1000 patient days for daptomycin and linezolid to 
the mean for our comparator institutions (see Table A and Table B above) -- a reduction in 
DOT/1000 patient days of 6%.  
Describe how you plan for the project outcomes to be broadly disseminated. 
The MGH Academy routinely shares acquired data with participants in order to foster inter-
activity and reinforce the application of new knowledge. For example, clinicians who take our 
American Board of Psychiatry and Neurology (ABPN) Maintenance of Certification self-
assessment modules are given individualized scoring reports that allow them to compare their 
own scores to national aggregate performance.  
The Academy will also share research findings and outcomes data via its dissemination e-
newsletter, which has a distribution of 40,000.  11 
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The research team will submit findings from the survey to the 2014 ISDA annual meeting. These 
findings will also be submitted for publication in a peer-reviewed journal (working title: “Survey 
of Clinician Knowledge of Appropriate Antimicrobial Utilization”). The findings of the post-
prescription audit in multidisciplinary rounds will be submitted to the 2015 IDSA annual 
meeting, and to a peer-reviewed journal (working title: “The Impact of Targeted Education of 
Clinicians on Appropriate Utilization of Linezolid and Daptomycin”).  
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3) Detailed Workplan and Deliverables Schedule 
 
Date  Step/Deliverable 
1/1/2013  Begin REDCap clinician survey design and beta testing. 
2/1/2013  Complete REDCap survey design and submission to Partners IRB for approval 
4/1/2013- 
4/14/2013 
Implementation of clinician survey (Stage A). 
4/15/2013  Begin development of educational material. 
4/15/2013  Begin multidisciplinary daily rounds with physician feedback (Stage B). 
6/1/2013  Complete development of educational material. 
7/1/2013  Begin Learning Management System exercises (ILMs, CSAT). (Stage B). 
4/1/2014-
4/14/2014 
Clinician post-intervention survey. (Stage C). 
5/15/2014  Submission of survey findings to IDSA 2014 (October 2014 conference). 
7/31/2014  Complete clinician post-intervention survey. 
8/1/2014  Begin analysis of pre- and post- intervention survey results. 
8/1/2014  Begin analysis of post-prescription auditing pre- and post- intervention. 
9/1/2014  Submit preliminary findings to Infectious Diseases Society of America annual 
meeting. 
12/1/2015  Begin manuscript preparation. 
12/31/2014  Complete analysis of program’s impact on antimicrobial utilization (via analysis 
of post-prescription auditing and clinician survey). 
5/15/2015  Submission of program impact analysis to ISDA 2015 (October 2015 conference). 
7/1/2015  Complete manuscript; submit to peer-reviewed medicine journal.  